James C. Mulloy, PhD

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Wunderlich, M; Manning, N; Sexton, C; O’Brien, E; Byerly, L; Stillwell, C; Perentesis, JP; Mulloy, JC; Mizukawa, B. Frontiers in Oncology. 2021; 11:642466.

Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Su, R; Dong, L; Li, Y; Gao, M; Han, L; Wunderlich, M; Deng, X; Li, H; Huang, Y; Gao, L; et al. Cancer Cell. 2020; 38:79-96.e11.

Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL. Rodriguez, S; Abundis, C; Boccalatte, F; Mehrotra, P; Chiang, MY; Yui, MA; Wang, L; Zhang, H; Zollman, A; Bonfim-Silva, R; et al. Leukemia. 2020; 34:1241-1252.

Asymmetrically Segregated Mitochondria Provide Cellular Memory of Hematopoietic Stem Cell Replicative History and Drive HSC Attrition. Hinge, A; He, J; Bartram, J; Javier, J; Xu, J; Fjellman, E; Sesaki, H; Li, T; Yu, J; Wunderlich, M; et al. Cell Stem Cell. 2020; 26:420-430.e6.

Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies. Khodoun, MV; Morris, SC; Angerman, E; Potter, C; Schuman, R; Wunderlich, M; Maciag, JJ; Locker, KC S; Mulloy, JC; Herr, AB; et al. Journal of Allergy and Clinical Immunology. 2020; 145:907-921.e3.

Improved chemotherapy modeling with RAG-based immune deficient mice. Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O'Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC. PloS one. 2019; 14:e0225532.

Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement. Wunderlich, M; Chen, J; O'Brien, E; Manning, N; Sexton, C; Byerly, L; Perentesis, JP; Mizukawa, B; Mulloy, JC. Blood. 2019; 134:3766.

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways. Melgar, KM; Jones, LM; Walker, M; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, K; Zhang, X; Sutter, P; et al. Blood. 2019; 134:3934.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al. Science Translational Medicine. 2019; 11:eaaw8828.

Epigenetic Regulator Genes Direct the Fate of Multipotent Progenitor Cell of Origin in Lineage Switched MLL-AF4 Leukaemia. Tirtakusuma, R; Milne, P; Ptasinska, A; Meyer, C; Nakjang, S; Komkov, A; Williamson, D; Cauchy, P; Assi, S; Blair, H; et al. 2019.